Best Practice and Research. Clinical Haematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

How should we treat the AYA patient with newly diagnosed ALL?
Publication date: Available online 3 August 2017 Source:Best Practice & Research Clinical Haematology Author(s): Nicolas Boissel Adolescent and young adult (AYA) patients with acute lymphoblastic leukaemia (ALL) are recognized as a unique population with specific characteristics and needs. In adolescents aged 15–20 years old, the use of full paediatric protocols is supported by many comparative studies of paediatric and adult cooperative groups. In young adults, growing evidence suggests that paediatric-inspired approaches may also improve outcomes and lead to long-term survival rates of almost 70%. In the las...
Source: Best Practice and Research Clinical Haematology - August 3, 2017 Category: Hematology Source Type: research

Pharmacogenomics in acute lymphoblastic leukemia
Publication date: Available online 27 July 2017 Source:Best Practice & Research Clinical Haematology Author(s): Shawn H.R. Lee, Jun J. Yang Pharmacogenomics is a fast-growing field of personalized medicine using a patient's genomic profile to determine drug disposition or response to drug therapy, in order to develop safer and more effective pharmacotherapy. Childhood acute lymphoblastic leukemia (ALL), being the most common malignancy in childhood, which is treated with uniform and standardized clinical trials, is remarkably poised for pharmacogenomic studies. In the last decade, unbiased genome-wide associati...
Source: Best Practice and Research Clinical Haematology - July 27, 2017 Category: Hematology Source Type: research

What is the optimal initial management of the older MCL patient?
Publication date: Available online 19 July 2017 Source:Best Practice & Research Clinical Haematology Author(s): Johanna C. Kluin-Nelemans, Jeanette K. Doorduijn The current first line treatment of a patient with mantle cell lymphoma (MCL) is often considered as too toxic for elderly patients. The elderly, however, comprise the majority of the patients with MCL. The results of several recent studies have shown that the outcome of this patient group is not as dismal as in the past. Indeed, if patients are not considered frail, and can tolerate rituximab and moderate intensive chemotherapy such as R-CHOP followed ...
Source: Best Practice and Research Clinical Haematology - July 20, 2017 Category: Hematology Source Type: research

Which patients should I transplant with acute lymphoblastic leukemia?
Publication date: Available online 13 July 2017 Source:Best Practice & Research Clinical Haematology Author(s): Tsofia Inbar, Jacob M. Rowe, Netanel A. Horowitz Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia (ALL) offers curative therapy for patients who are in complete remission. Historically, there was great hesitation to offer this modality to patients with ALL due to the high attendant morbidity and mortality. Furthermore, the outstanding results in childhood ALL led many to believe that significant long-term survival could be achieved using chemotherapy-based regimens alone...
Source: Best Practice and Research Clinical Haematology - July 13, 2017 Category: Hematology Source Type: research

Acute lymphoblastic leukemia (ALL)
Publication date: Available online 11 July 2017 Source:Best Practice & Research Clinical Haematology Author(s): Anjali Advani (Source: Best Practice and Research Clinical Haematology)
Source: Best Practice and Research Clinical Haematology - July 11, 2017 Category: Hematology Source Type: research